<DOC>
	<DOC>NCT01095081</DOC>
	<brief_summary>Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with GadovistÂ®. For each patient, the treating physician or nurse documents demographics, medical data, safety parameters and treatment signs and symptoms at the visit. Patients with severe renal impairment will be followed-up after 3 month by phone call from the investigator if in line with routine practice. Data audit/monitoring by source data verification will be done in a subset of sites and patients</brief_summary>
	<brief_title>GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients</brief_title>
	<detailed_description>Evaluate the safety and tolerability of Gadovist in patients requiring contrast-enhanced MRI.</detailed_description>
	<criteria>Patients undergoing contrast enhanced Magnetic Resonance Imaging with Gadobutrol (Gadovist). There are no other exclusion criteria beyond the contraindications contained in the Summary of Product Characteristics (hypersensitivity to the active substance or to any of the excipients) and the warnings.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>